Pay in 4 interest-free payments of $6.44 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
Prescribe the identical injection for obesity alone and Medicare is legally forbidden to pay
Semaglutide, a novel GLP-1 receptor agonist, was investigated in a recently completed phase 2 placebo-controlled trial comparing the efficacy and safety of different doses in 320 NASH patients and the results are awaited (NCT02970942)
More serious but less common adverse effects warrant clinical attention
The 12 mg group achieved 24.2% weight loss at 48 weeks in Phase 2, and 28.7% at 68 weeks in the Phase 3 TRIUMPH-4 trial
Detoxification : Cleanses the body of harmful toxins, which can have a positive impact on overall skin health
US$ 29.34
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
US$ 21.33
US$ 28.83
US$ 21.17
US$ 27.65
